Nuros Ltd is a new supplier of medical devices to health services in the UK, specialising in products associated with the treatment of arterial and vascular disease. Nuros is positioned to provide 'a real alternative' to the large global companies that currently dominate the sector. The company plans to achieve this by bringing together complimentary products from selected manufacturing sources to form a cohesive and comprehensive range and through a heavily European ethos and culture. Rather than trading as a general devices supplier, Nuros Ltd addresses a specific disease area with a clear focus upon products required for the treatment of peripheral vascular disease.
The Nuros team will work in partnership with physicians, having the specialised expertise to discuss cases, treatment options and new technologies and procedures. Being responsive and highly specialised it will be ideally placed to bring new technologies to the UK market as they emerge.
The product range combines advanced features and specifications with proven quality and reliability and includes:
• Aortic stent-graft systems
• Heparin-bonded, ePTFE peripheral and access grafts
• Knitted and woven, collagen impregnated, polyester grafts
• Branched thoracic polyester grafts
• Carotid patches and shunts
• Self-expanding stents
• PTA catheters and inflation devices
• Embolectomy (including double-lumen), thrombectomy and occlusion catheters
• Arterial, venous and peelable introducers
• Haemostatic valves
• Torque devices
• Atraumatic vessel clips and vessel loops
• Vein strippers
The range will grow further over coming months with launches planned for additional endovascular stent-grafts, balloon expandable iliac and renal stents and carotid stents.
This impressive, and almost entirely European product portfolio is offered with exceptional levels of customer service and extremely competitive pricing.
Nuros fills the gap between the large global companies with their own direct operations, and small companies who would normally work through independent multi-sector distributors and who are disadvantaged by a limited range and remoteness from the marketplace. By bringing together such sources to form a new, comprehensive and dedicated range, Nuros claims the customer will at last have 'a real alternative'. Manufacturers will benefit from having a strong partner in the market that can work closely with them on product development, clinical and marketing trials.
The founder of the Company, John Howard, joined Impra in 1991 as MD of their UK subsidiary achieving strong, sustained growth and market leadership. Following Impra's acquisition by Bard in 1996, he managed the combined UK businesses before being promoted to European Marketing Director in 1999.
John has been delighted by the very positive responses from customers in the early days of activity. He and his team look forward with enthusiasm to building Nuros into a first-choice supplier in the peripheral vascular market. For further information on the product range, Email enquiries@nuros.co.uk or visit
www.nuros.co.uk.
